Haemonetics Q4 EPS of $1.29 Beats Estimates, Up 4% Year-over-Year
Haemonetics generated fiscal fourth-quarter adjusted earnings of $1.29 per share, beating the consensus estimate by $0.01 and up 4% from $1.24 a year earlier. The company also reported revenue growth that surpassed analyst forecasts for the quarter.
1. Q4 Earnings Beat
Haemonetics reported adjusted EPS of $1.29 for fiscal fourth quarter, surpassing the consensus estimate of $1.28 per share by $0.01.
2. Year-over-Year Growth
The $1.29 per share represents a 4% increase compared with $1.24 in the fourth quarter of the prior year, driven by improved operational efficiencies.
3. Revenue Performance
Total revenue for the quarter exceeded analyst forecasts, reflecting strong demand across the company’s blood management and diagnostic technologies business lines.
Related News
JPM
J.P. Morgan Joins SpaceX $1.75 Trillion Nasdaq IPO With $1.45B Bitcoin Disclosure
JPM•
MWC
Micware Co. Soars 51.5% in IPO Debut, Raises $22.8M
MWC•
NVDA
Nvidia posts $81.6bn Q1 revenue, raises dividend 25-fold and authorizes $80bn buyback
NVDA•
URBN
Urban Outfitters Q1 Sales Soar 11% to $1.5B, EPS Up 12%
URBN•
ODV
Osisko Development Raises US$275M via 4.125% Convertible Notes with 25% Premium
ODV•
Sources
FZ